SynthesisInternational journal of clinical pharmacy2026
Adherence to biologics in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Synthesis in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.Frontiers in immunology · 2026Article
- Drug-associated postpartum hemorrhage: a comprehensive disproportionality analysis based on the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdherence to biologics is crucial for the effective management of patients with inflammatory bowel disease (IBD). However, comprehensive data on the prevalence of adherence is still lacking.
aimThis systematic review and meta-analysis aimed to estimate the prevalence of adherence to biologics among adult patients with IBD and to identify the factors influencing adherence.
methodWe conducted a systematic search of PubMed, Embase, Scopus, CINAHL, Web of Science, the Cochrane Library, and three Chinese databases for relevant observational studies published between January 1, 2010, and March 15, 2025. A random-effects model was employed to calculate the pooled prevalence of adherence. Heterogeneity and publication bias were assessed. We classified the identified influencing factors and conducted a narrative synthesis to summarize the findings.
resultsThis review included 29 studies involving 44,397 patients with IBD from 14 countries. The pooled prevalence of adherence to biologics was 70% (95% CI 66%-75%, I
conclusionThe results suggested that adult patients with IBD exhibit moderately high levels of adherence to biologics. Gender and insurance status were factors associated with adherence. Given that these conclusions are limited by heterogeneity and methodological diversity, further validation through high-quality studies is required.
Indexed as
Identifiers
41369787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.